Angiodynamics (ANGO) Depreciation & Amortization (CF) (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $5.6 million in Q2 2026.

• Quarterly Depreciation & Amortization (CF) fell 4.05% year-over-year to $5.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $23.0 million (down 11.03% YoY) and the FY2026 annual result came in at $23.0 million, down 11.03% from the prior year.
• Depreciation & Amortization (CF) held at $5.6 million in Q2 2026, from $5.6 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.8 million in Q1 2023 to a low of $5.6 million in Q1 2026.
• A 5-year average of $6.8 million and a median of $6.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) rose 17.52% — and 2025, when it slipped 16.26%.
• Tracing ANGO's Depreciation & Amortization (CF) over 5 years: stood at $7.8 million in 2022, then slipped by 14.49% to $6.7 million in 2023, then grew by 2.66% to $6.9 million in 2024, then slipped by 16.26% to $5.7 million in 2025, then slipped by 2.61% to $5.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $5.6 million (Q2 2026), $5.6 million (Q1 2026), and $5.7 million (Q4 2025), per Business Quant data.